drugset
drugset / Trial / NCT04493541

A Study to Assess the Safety and Drug Levels of BMS-986256 in Participants With Active Cutaneous Lupus Erythematosus

NCT04493541 ↗

Phase 1 Completed 13 enrolled Bristol-Myers Squibb
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the safety and drug levels of BMS-986256 in participants with cutaneous lupus erythematosus.

Timeline

Start
2020-08-26
Primary completion
2023-04-21
Completion
2023-04-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Afimetoran Small molecule — —

Indications

cutaneous lupus erythematosus